Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.
Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.
Evotec is built on integrated drug discovery know-how of more than 15 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operations are based in Abingdon, UK, Göttingen, Munich, Germany, San Francisco and Branford, USA. Evotec has more than 600 employees worldwide.
Action Plan 2016 - Evotec´s offering for Innovation Efficiency
The core elements of this strategy are:
1. EVT Execute
- Stand-alone screening, medicinal chemistry, compound management, compound profiling,…
- Highest quality solution tools and processes
- No risk-exposure, lower margin, but long-term repeat business
2. EVT Integrate
- Integrated drug discovery alliances on partner targets
- Best-in-class integrated drug discovery alliances (multi-target projects)
- Risk-shared performance-based alliances with research fees, milestones and royalties
3. EVT Innovate
- CureBeta, CureNephron,..Product Development Partnerships
- First-in-class discovery and product development innovations
- Modest R&D investment for high upfront, higher milestone and higher royalty alliances